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OBJECTIVES: Endocrine therapies in the treatment of breast
cancer include tamoxifen, and aromatase inhibitors such as anas-
trozole. Anastrozole has demonstrated superior efﬁcacy over
tamoxifen in reducing disease recurrence in an EBC population
and is associated with a number of important tolerability bene-
ﬁts over tamoxifen. This study aimed to examine the differences
in preferences between anastrozole and tamoxifen as adjuvant
treatment for breast cancer. METHODS: Eighty-ﬁve women
aged 50–83 (mean 61) years were recruited from the Australian
general public. Participants completed questions regarding expe-
rience with breast cancer and undertook a discrete choice task.
The attributes used in the WTP scenarios included values for risk
of breast cancer recurrence, hot ﬂushes, vaginal abnormalities,
and cardiovascular events (in favour of anastrozole) and mus-
culoskeletal disorders and fracture (in favour of tamoxifen), and
cost. The risk estimates were derived from clinical sources.
RESULTS: A total of 74 subjects provided evaluable data. Eleven
subjects were excluded because they were non-traders (3) or irra-
tional in their choice task. The total WTP for anastrozole over
tamoxifen was $AUS673.40 per month (95% CI: 390.6–1044.0)
for 3–5 years. This included a WTP of AUS$267.00,
AUS$237.10 and AUS$276.90 for the reduced risk associated
with anastrozole for breast cancer recurrence, vaginal abnor-
malities and cardiovascular events, respectively. For the reduced
risk of musculoskeletal disorders and fractures associated with
tamoxifen, a negative WTP of -AUS$67.80 was obtained. A neg-
ative point estimate was obtained for hot ﬂushes (-AUS$39.80).
CONCLUSIONS: On average, subjects were willing to pay
AUS$673.40 per month for 3–5 years for the attributes of anas-
trozole over tamoxifen, placing higher value on reduced risk of
recurrence, vaginal abnormalities and cardiovascular disease
than hot ﬂushes, musculoskeletal disorder and fracture.
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OBJECTIVES: Colorectal cancer is one of the most common
forms of cancer in Europe and the USA. The aim of this study
was to assess prospectively changes of quality of life after surgery
for rectal cancer with a focus on sexuality and gender related
differences. METHODS: Since 1998, the EORTC-QLQ-C-30
and a tumor speciﬁc ad-hoc module were prospectively admin-
istered to patients before surgery, at discharge, 3, 6, 12 and 24
months postoperatively. These data were combined with QoL
data from a historical cohort of patients that underwent surgery
between 1992 and 1997. Altogether, 819 patients with rectum
and sigma carcinoma were included in the analysis, 541 of them
provided QoL data for at least 1 time point. Comparisons were
made between female and male patients. Due to skewed distrib-
utions, non-parametric statistical analyses were performed. A
global alpha of p < 0.05 was considered signiﬁcant. RESULTS:
In total, 262 female and 279 male patients provided QoL data.
Both groups were comparable in terms of age, tumor stage and
surgical procedure. In men as well as women most QoL scores
dropped signiﬁcantly below baseline in the early postoperative
period. From the third month onwards, global health, emotional
and physical functioning improved. Female gender was associ-
ated with signiﬁcantly worse global health and physical func-
tioning and with higher scores on treatment strain and fatigue.
Men reported more difﬁculties with sexuality. These problems
tended to remain. CONCLUSIONS: These ﬁndings conﬁrm that
QoL changes post surgery and is different between men and
women. Women appear to be affected by impaired physical func-
tioning and global health. Female gender is associated with sig-
niﬁcantly higher fatigue levels and increased strain values after
surgery. In terms of impaired sexual enjoyment, men are put
more under strain than woman. All differences between men and
women remain stable in the course of time.
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OBJECTIVES: Prostate cancer is one of the most common forms
of cancer in Europe and the USA. Predominant symptoms in
these patients are erectile dysfunctions and urinary problems.
Since decreases of these functions can be attributed to disease
and treatment but also to age, we studied a German reference
population measuring as well general QoL as prostate speciﬁc
symptoms. Data from this study can be used as control group in
studies with older men treated for prostate cancer. METHODS:
In cooperation with a German health insurance company 3000
questionnaires were mailed to a randomly selected sample of
men aged 45–75 years. General and disease targeted health
related quality of life was measured using the EORTC QLQ-
C30, a recently validated prostate speciﬁc module, the EQ-5D
and the Patient Oriented Prostate Utility Score (PORPUS). A
total of 1129 (37.6%) questionnaires were returned. We com-
pared QoL data from this new reference population to QoL data
from a historical cohort of 950 patients following prostatectomy
or radio therapy, in which the same set of questionnaires was
used. RESULTS: Mean age was 56.8 years. In terms of general
QoL (QLQ-C30), the reference population showed similar QoL
scores as prostatectomy patients but better scores than radio
therapy patients. On the prostate speciﬁc module, the reference
sample showed better QoL but a high extent of erectile dys-
function, urinary problems and psychic strain. More than 1/3 of
the patients (39.0%) from the reference population reported
some degree of urinary problems, 63.2% reported a decrease of
sexual activity. CONCLUSIONS: Taking into account the sensi-
tive topic of this study, a response rate of 37.6% is more than
satisfying. Older men in our randomly selected, population based
sample do not show perfect erectile and urinary function. These
ﬁndings should be kept in mind when interpreting QoL data of
prostate cancer patients.
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OBJECTIVES: Cost of management of toxicity associated with
chemotherapy can be considerable. We estimated costs of treat-
ing drug-related adverse events associated with pemetrexed or
docetaxel as second-line therapy for non-small cell lung cancer
(NSCLC). METHODS: Resource utilisation (RU) data (hospital
admissions, concomitant medications, transfusions) were col-
lected prospectively during a multinational, randomised phase III
trial comparing pemetrexed 500mg/m2 and docetaxel 75mg/m2,
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both administered every 21 days. Clinic visits were estimated
from grade four toxicities not requiring hospitalisation. Using
the perspective of the national health care system, Spanish costs
were applied to RU data from patients who received treatment
(N = 541). Unit costs were obtained from published sources.
Mean cost per patient was calculated. RESULTS: Baseline char-
acteristics were well-balanced (72% male, 88% performance
status 0/1, 75% Stage IV). Patients received a median of four
cycles in both treatment arms. Survival was similar between arms
(HR = 0.99), with a median of about eight months. Grade 3/4
neutropenia and neutropenic fever occurred more frequently
with docetaxel (40% vs. 5%, 13% vs. 2%, respectively; p <
0.001). Most other grade 3/4 toxicities occurred at low rates
(£5%) and were similar between arms. Patients receiving doc-
etaxel were hospitalised more frequently and received more gran-
ulocyte colony-stimulating factors, erythropoietin, antibiotics
and antifungals. Patients receiving docetaxel were more likely to
incur extra clinic visits to manage grade four toxicity. Patients
treated with pemetrexed received more transfusions. Total mean
cost per patient was 309€ for pemetrexed and 1036€ for doc-
etaxel. Hospitalisation and outpatient medications accounted for
majority of costs (67% and 25% in the pemetrexed group,
respectively, and 77% and 21% in the docetaxel group, respec-
tively). CONCLUSIONS: Pemetrexed demonstrated similar efﬁ-
cacy to docetaxel in second-line treatment of NSCLC, but with
a superior toxicity proﬁle. The differences in toxicity are
expected to translate to considerable cost savings to the Spanish
health care system.
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OBJECTIVES: Health-related quality of life assessments are
increasingly used in clinical decision-making. A phase III trial of
pemetrexed versus docetaxel in second-line therapy for advanced
non-small cell lung cancer (NSCLC) showed similar efﬁcacy;
however, key safety beneﬁts were reported with pemetrexed. Fol-
lowing a pilot study in the UK (UK), an expanded study in the
UK and France was conducted to determine patient value asso-
ciated with individual toxicity proﬁles. METHODS: A discrete
choice conjoint analysis was used to quantify patient preference
and willingness-to-pay for chemotherapy. A review of trial data,
along with expert opinion, identiﬁed clinically meaningful toxi-
cities that were statistically signiﬁcantly different. Levels of risk
of: febrile neutropenia (requiring hospitalisation) and nausea,
neuropathy, arthralgia/myalgia, alopecia (all grades), were eval-
uated in the pilot. Following the pilot, arthralgia/myalgia was
removed and a sample size of 70 pre-treated NSCLC patients per
country was calculated. Patients considered unique, randomly
generated sets of 10 pair-wise choice scenarios representing levels
for toxicity attributes plus cost, designed to elicit trade-offs.
Logistic regression analysis was applied to the stated scenario
preferences against the individual attribute levels. RESULTS: In
the expanded study, patients (N = 140) were predominantly
male, mean age 61 years, and 60% Stage III, which is compara-
ble to the pilot. Pemetrexed would be accepted in preference to
docetaxel at zero cost, with a probability of 0.81 in the UK and
0.90 in France. The probability of choosing pemetrexed over
docetaxel decreases with increasing cost; however, patient pref-
erence remains strong at 0.70 in the UK and 0.85 in France with
a cost per cycle of £400 and 2500€, respectively. CONCLU-
SIONS: NSCLC patients showed clear preference for the
enhanced toxicity proﬁle with pemetrexed, which translates to
valuable quality of life gains in the second-line setting. These
data provide sensitive strength of preference measures. Addi-
tional country studies are planned.
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OBJECTIVES: To identify and describe currently available
instruments to measure patient-reported outcomes and percep-
tions of cancer-related fatigue. METHODS: A literature review
was performed in several electronic sources including the U.S.
National Cancer Institute website and the Medline database
(1966–2004) using the keywords: fatigue, asthenia, question-
naire, scale, instrument, oncology, cancer, assessment, measure,
measurement, expectation/s, relief, satisfaction, perception/s,
worry/ies. Articles located were hand-searched for further rele-
vant articles. A citation was selected for review when it referred
to the use or development of patient reported instrument(s) to
measure the impact of cancer-related fatigue or its treatment
and/or patients expectations, beliefs and concerns regarding
cancer-related fatigue. For each questionnaire located the fol-
lowing data was reviewed: instruments’ name, target population,
item number, dimensions, response scale and time frame.
RESULTS: In total, 35 citations were selected and reviewed,
which referred to 30 different instruments (27 patient-reported
outcome questionnaires –PRO’s– and 3 epidemiological survey
instruments) used to measure several aspects of cancer-related
fatigue. Questionnaires ranged from a single item to 40 items,
and the number of dimensions from 1 to 7. Almost all of the
PRO’s focused on aspects such as the intensity, frequency and
duration of fatigue, though some also measured one or more of
the following: quality of life, distress, psychological impact and
impact on motivation/activity, and barriers to patient-physician
communication. The survey instruments located were more
likely to focus on patient’s attitudes and beliefs regarding 
physician-patient interaction, psychosocial issues, accessing
information, satisfaction with fatigue management and percep-
tions of causes, among others. CONCLUSIONS: Though there
appears to be a surfeit of instruments to measure the intensity,
frequency and duration of cancer-related fatigue, and some
emphasis on the way fatigue affects quality of life there are few
instruments which incorporate other aspects such as beliefs,
expectations and attitudes which may also be useful in clinical
practice.
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OBJECTIVES: To determine the preferences of the general public
for health state descriptions of anaemia associated with cancer
treatment. The majority of patients undergoing chemotherapy
develop anaemia which leads to fatigue, and decreased quality
of life (i.e. associated with a haemoglobin under 12g/dl). Treat-
ing cancer related fatigue has not been given the importance of
